Air Force veteran Andrin Jones, of Matteson, was diagnosed with prostate cancer three years ago but survived because it was ...

Seven-year follow-up data on over 1400 patients show radium-223's long-term safety, with a low 2% secondary malignancy rate, reflecting real-world use.

Dr. Joshua K. Sabari and Dr. Daniel V. Araujo provide expert insights into genitourinary cancer updates from ASCO 2025.

BMS entered the radiopharma space via its $4.1 billion buyout of RayzeBio at the end of 2023. Unlike Novartis’ approved ...

A recent study from the Institute of Biomedicine at the University of Eastern Finland shows that the glucocorticoid receptor can both promote and ...

Acupuncture produced significantly greater reductions in nocturia episodes and IPSS scores in survivors of prostate cancer ...

How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.

Jay Harris, who has anchored for SportsCenter for over 10 years has shared he has been diagnosed with prostate cancer and ...

Investigators created a prognostic digital pathology-based AI score to identify a subset of patients with clinically high-risk prostate cancer more likely to benefit from the addition of abiraterone ...

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, has updated ...

Adding niraparib to AAP and ADT improved rPFS in mCSPC patients with HRR mutations in the phase 3 AMPLITUDE trial.